UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-A

 

For Registration of Certain Classes of Securities

Pursuant to Section 12(b) or (g) of the

Securities Exchange Act of 1934

 


 

Osmotica Pharmaceuticals plc

(Exact name of registrant as specified in its charter)

 

Ireland

 

Not Applicable

(State or other jurisdiction of incorporation or
organization)

 

(I.R.S. Employer Identification No.)

 

400 Crossing Boulevard
Bridgewater, NJ 08807
United States

 

08807

(Address of principal executive offices)

 

(Zip Code)

 


 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class
to be so registered

 

Name of each exchange on which
each class is to be registered

Ordinary Shares, nominal value $0.01 per share

 

The NASDAQ Stock Market LLC

 


 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.    x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.    o

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. o

 


 

Securities Act registration statement or Regulation A offering statement file number to which this form relates (if applicable): 333- 227357

 

Securities to be registered pursuant to Section 12(g) of the Act: None

 

 

 


 

Item 1. Description of Registrant’s Securities to be Registered.

 

Osmotica Pharmaceuticals plc (the “Registrant”) hereby incorporates by reference the description of its ordinary shares, nominal value $0.01 per share, to be registered hereunder, contained under the heading “Description of Share Capital” in the Registrant’s Registration Statement on Form S-1 (File No. 333-227357) (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”). Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Act that constitutes part of the Registration Statement shall also be deemed to be incorporated herein by reference.

 

Item 2. Exhibits.

 

Pursuant to the Instructions as to Exhibits, no exhibits are filed herewith or incorporated herein by reference.

 

2


 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Date: October 18, 2018

OSMOTICA PHARMACEUTICALS PLC

 

 

 

 

By:

/s/ Brian Markison

 

Name:

Brian Markison

 

Title:

Chief Executive Officer

 

3